Published in Clinical Oncology Week, November 21st, 2005
"[Our goal was] to determine whether use of the DRE results in decreased participation in prostate cancer (PCa) screening, which, in turn, would result in lower detection. Population based PCa screening includes prostate-specific antigen (PSA) measurement with or without a DRE. PSA and DRE screening provide greater sensitivity than PSA alone; however, the increased participation rate resulting from PSA-alone screening may result in a greater detection rate," scientists writing in the journal Urology reported.
"We performed a survey...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.